NetworkNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD

NetworkNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Reports on Publication of Low-Dose Suramin for ASD Research

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, announced that its groundbreaking research will be published in the “Annals of General Psychiatry,” an internationally recognized scientific psychiatry publication. The research was reported in a manuscript titled “Randomized clinical trial of low-dose suramin intravenous infusions for treatment of autism spectrum disorder,” which will be published by the psychiatry publication. Written by PaxMedica chief medical officer Dr. David Hough, MD, along with nine coauthors, the article reports on the potential of monthly suramin intravenous infusions as a safe and potentially efficacious treatment for the core symptoms of autism spectrum disorder (“ASD”). Coauthors of the article include Alice Mao, MD; Michael Aman, PhD; Reymundo Lozano, MD, MS; Constance Smith-Hicks, MD, PhD; Veronica Martinez-Cerdeno, PhD; Michael Derby; Zachary Rome; Miel Malan, MD; and Robert Findling, MD. An open access journal emphasizing a biopsychosocial approach to illness and health, the “Annals of General Psychiatry” supports the principles of evidence-based medicine, further validating the significance of this research. “The acceptance of this manuscript represents a significant milestone in PaxMedica’s continued dedication to pioneering innovative treatments for autism spectrum disorder,” said PaxMedia chief medical officer Dr. David Hough in the press release. “We are honored to contribute to the field of psychiatry with this significant research, underscoring our commitment to advancing the understanding and treatment of ASD.”

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer